Key result
Dual antiplatelet therapy continued beyond one year after coronary stenting requires balancing the associated ischemic and bleeding risks.
Why the study?
Does dual antiplatelet therapy continued beyond a year after coronary stenting affect cardiovascular and bleeding events?
Does dual antiplatelet therapy continued beyond a year after coronary stenting affect cardiovascular and bleeding events?
This commentary discusses the balance of ischemic and bleeding risks associated with prolonged dual antiplatelet therapy after coronary stenting.
This commentary discusses a study published in JAMA Cardiology that assessed the prognosis of cardiovascular and bleeding events associated with dual antiplatelet therapy continued beyond a year after coronary stenting.
No takes yet. Share an insight, caveat, or question.
Glenn N. Levine (2017) studied this question. Dual antiplatelet therapy continued beyond one year after coronary stenting requires balancing the associated ischemic and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: